Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Employees - 5, CEO - Jonathan Kaufman, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -12.49, Piotroski Score(max is 10): 2, Working Capital: $1436889000, Total Assets: $2349810000, Retained Earnings: $-19228194000, EBIT: -1258182770, Total Liabilities: $862215000, Revenue: $173666

- Current Price $ - Analyst Target Price $